Introduction: For over 50 years, vitamin K antagonists such as warfarin (Aldocumar®) and
acenocoumarol (Sintrom®) have been the gold standard for reducing the risk of …

Background Four novel direct oral anticoagulants (DOACs) named dabigatran, rivaroxaban,
edoxaban and apixaban have been recently introduced to overcome some of the drawbacks …

Background A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and
edoxaban) with clear advantages over classic dicoumarin oral anticoagulants (warfarin and …

Warfarin has been the primary anticoagulant drug used in the USA for more than 50 years.
However, 2 novel types of oral anticoagulants have recently been approved for use in the …

The oral anticoagulant therapy is used for the cure and the prevention of thromboembolic
diseases. In the last fifty years the warfarin has been considered the oral anticoagulant of …

Background Anticoagulation therapy is used in several conditions to prevent or treat
thromboembolism. A new group of oral anticoagulants with clear advantages over classic …

Anticoagulation therapy is indicated in several conditions to prevent, treat, or reduce the
recurrence risk of thromboembolism. Included in these conditions are: deep vein thrombosis …

Background Anticoagulation therapy is used in several conditions to prevent or treat
thromboembolism. Recently, new oral anticoagulants have been introduced as alternatives …

Abstract Objective: Rivaroxaban, apixaban, edoxaban, and dabigatran are the first direct
oral anticoagulants (DOACs) to be cleared by the Food and Drug Administration for …

Several new oral anticoagulants have been studied in the past decade, and have now
started to enter the market. These drugs are reported to be as effective as, or more effective …